Weight-loss drugs, particularly newer options like GLP-1 receptor agonists, are revolutionising the treatment of obesity and ...

But what makes Altimmune's drug different from existing drugs, and what kind of market opportunity does it have? Altimmune's ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on 89bio (ETNB – Research Report) yesterday and set a price target of $12.00.